Table II.
Correlation of clinicopathologic characteristics with EBI3 expression
| EBI3 expression (n=312) | |||||
|---|---|---|---|---|---|
| Characteristic | Total | Low | High | P-value | χ2 |
| Age (years) | |||||
| ≤52 | 155 | 97 | 58 | 0.472 | 0.5178 |
| >52 | 157 | 92 | 65 | ||
| Sex | |||||
| Female | 47 | 27 | 20 | 0.634 | 0.2270 |
| Male | 265 | 162 | 103 | ||
| HBsAg | |||||
| No | 52 | 35 | 17 | 0.277 | 1.1837 |
| Yes | 260 | 154 | 106 | ||
| AFP (ng/ml) | |||||
| ≤20 | 121 | 59 | 62 | 0.001 | 11.5567 |
| >20 | 191 | 130 | 61 | ||
| Liver cirrhosis | |||||
| No | 33 | 19 | 14 | 0.709 | 0.1392 |
| Yes | 279 | 170 | 109 | ||
| γ-GT (U/L) | |||||
| ≤54 | 148 | 85 | 63 | 0.280 | 1.1658 |
| >54 | 164 | 104 | 60 | ||
| Child-Pugh score | |||||
| A | 309 | 186 | 123 | 0.160 | 1.9713 |
| B | 3 | 3 | 0 | ||
| Tumor differentiation | |||||
| I–II | 232 | 126 | 106 | <0.001 | 14.8784 |
| III–IV | 80 | 63 | 17 | ||
| Tumor size (cm) | |||||
| ≤5 | 207 | 115 | 92 | 0.011 | 6.4941 |
| >5 | 105 | 74 | 31 | ||
| Tumor number | |||||
| Single | 270 | 162 | 108 | 0.597 | 0.2795 |
| Multiple | 42 | 27 | 15 | ||
| Encapsulation | |||||
| None | 172 | 101 | 71 | 0.457 | 0.5529 |
| Complete | 140 | 88 | 52 | ||
| Tumor thrombus | |||||
| No | 227 | 129 | 98 | 0.027 | 4.9037 |
| Yes | 85 | 60 | 25 | ||
| TNM stage | |||||
| I | 138 | 73 | 65 | 0.013 | 6.1089 |
| II–III | 174 | 116 | 58 | ||
| BCLC stage | |||||
| A | 212 | 120 | 92 | 0.037 | 4.3722 |
| B/C | 100 | 69 | 31 | ||
Statistical analyses were performed using the χ2 test. AFP, alpha-fetoprotein; HBsAg hepatitis B surface antigen; γ-GT, γ-glutamyl transferase; BCLC stage, the Barcelona Clinic Liver Cancer stage.